The mouse light/dark box test

Arborelius, 1999, The role of corticotrophin-releasing factor in depression and anxiety, J. Endocrinol., 160, 1, 10.1677/joe.0.1600001 Barnes, 1990, Ketotifen and its analogues reduce aversive responding in the rodent, Pharmacol. Biochem. Behav., 37, 785, 10.1016/0091-3057(90)90564-X Barnes, 1992, Profiles of interaction of R(+)/S(−)-zacopride and anxiolytic agents in a mouse model, Eur. J. Pharmacol., 218, 91, 10.1016/0014-2999(92)90151-S Barnes, 1992, The interaction of R(+) and S(−) zacopride with PCPA to modify rodent aversive behaviour, Eur. J. Pharmacol., 218, 15, 10.1016/0014-2999(92)90142-Q Barret, 1993, 5-HT receptors as targets for the development of novel anxiolytic drugs/models, mechanisms and future directions, Psychopharmacology, 112, 1, 10.1007/BF02247357 Barry, 1987, A simple habituation test in the mouse, Br. J. Pharmacol., 92 Belzung, 1994, Comparison of different behavioural test situations used in Psychopharmacology for measurement of anxiety, Physiol. Behav., 3, 623, 10.1016/0031-9384(94)90311-5 Belzung, 1987, Anxiogenic effects of methyl-β-carboline-carboxylate in a light/dark choice situation, Pharmacol. Biochem. Behav., 28, 29, 10.1016/0091-3057(87)90006-2 Belzung, 1989, Behavioural effects of the benzodiazepine receptor partial agonist RO 16-6028 in mice, Psychopharmacology, 97, 388, 10.1007/BF00439456 Belzung, 1994, PD135158, a CCK-B antagonist, reduces “state”, but not “trait” anxiety in mice, Pharmacol. Biochem. Behav., 49, 433, 10.1016/0091-3057(94)90445-6 Bill, 1989, Actions of 5HT1A ligands and standard anxiolytics on mouse exploratory behaviour in a two compartment light: dark arena, Br. J. Pharmacol., 98 Bill, 1992, Behavioural studies of WAY 100289, a novel 5-HT3 receptor antagonist, in two animal models of anxiety, Eur. J. Pharmacol., 218, 327, 10.1016/0014-2999(92)90186-8 Blumstein, 1983, Further characterisation of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines, Pharmacol. Biochem. Behav., 18, 37, 10.1016/0091-3057(83)90247-2 Bodnoff, 1989, A comparison of the effects of diazepam versus several typical and atypical antidepressant drugs in an animal model of anxiety, Psychopharmacology, 97, 277, 10.1007/BF00442264 Borsini, 1993, The effects of DAU 6215, a novel 5HT3 antagonist in animal models of anxiety, Pharmacol. Res., 27, 151, 10.1006/phrs.1993.1015 Bourin, 1997, Animal models of anxiety: are they suitable for predicting drug action in humans?, Pol. J. Pharmacol., 49, 79 Bourin, 1998, Cholecystokinin as a target for neuropsychiatric drugs, Drug News Perspect., 11, 342, 10.1358/dnp.1998.11.6.657281 Bourin, 1996, A schematic representation of the psychopharmacological profile of antidepressants, Prog. Psychopharmacol. Biol. Psychiatry, 20, 1389, 10.1016/S0278-5846(96)00134-0 Bourin, 1998, Neurobiology of panic disorder, J. Psychosom. Res., 44, 161, 10.1016/S0022-3999(97)00203-1 Bourin, 2001, Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice, Behav. Brain Res., 124, 87, 10.1016/S0166-4328(01)00238-8 Cheng, 1994, Actions of 5-hydroxytryptophan to inhibit and disinhibit mouse behaviour in the light/dark test, Eur. J. Pharmacol., 255, 39, 10.1016/0014-2999(94)90080-9 Costall, 1992, Anxiolytic potential of 5-HT3 receptor antagonists, Pharmacol. Toxicol., 70, 157, 10.1111/j.1600-0773.1992.tb00448.x Costall, 1995, Behavioural interactions between 5-hydroxytryptophan neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations, Br. J. Pharmacol., 116, 2989, 10.1111/j.1476-5381.1995.tb15954.x Costall, 1997, The influence of 5-HT2 and 5-HT4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test, Br. J. Pharmacol., 122, 1105, 10.1038/sj.bjp.0701513 Costall, 1988, Actions of buspirone in a putative model of anxiety in the mouse, J. Pharm. Pharmacol., 40, 494, 10.1111/j.2042-7158.1988.tb05284.x Costall, 1988, Effects of the 5-HT receptors antagonist GR38032F, ICS 205-930 and BRL 43694 in tests for anxiolytic activity, Br. J. Pharmacol., 93 Costall, 1989, Exploration of mice in a black and white box: validation as a model of anxiety, Pharmacol. Biochem. Behav., 32, 777, 10.1016/0091-3057(89)90033-6 Costall, 1990, Sites of action of ondansetron to inhibit withdrawal from drugs of abuse, Pharmacol. Biochem. Behav., 36, 97, 10.1016/0091-3057(90)90132-2 Costall, 1991, Anxiolytic effects of CCK-B antagonists, Neuropeptides, 19, 65, 10.1016/0143-4179(91)90084-V Costall, 1993, The effect of the 5-HT3 receptor antagonist, RS 42358-197, in animal models of anxiety, Eur. J. Pharmacol., 234, 91, 10.1016/0014-2999(93)90710-Y Crawley, 1981, Neuropharmacologic specificity of a simple model for the behavioural actions of benzodiazepines, Pharmacol. Biochem. Behav., 15, 695, 10.1016/0091-3057(81)90007-1 Crawley, 1985, Exploratory behaviour models of anxiety in mice, Neurosci. Biobehav. Rev., 9, 37, 10.1016/0149-7634(85)90030-2 Crawley, 1982, Base line exploratory activity predicts anxiolytics responsiveness to diazepam in five mouse strains, Brain Res. Bull., 8, 609, 10.1016/0361-9230(82)90087-9 Crawley, 1980, Preliminary report of a simple animal behaviour for the anxiolytic effects of benzodiazepines, Pharmacol. Biochem. Behav., 13, 167, 10.1016/0091-3057(80)90067-2 Crawley, 1984, Absence of intrinsic antagonist actions of benzodiazepine antagonist on an exploratory model of anxiety in the mouse, Neuropharmacology, 5, 531, 10.1016/0028-3908(84)90026-1 Crawley, 1997, Behavioural phenotypes of inbred mouse strains: implication and recommendations for molecular studies, Psychopharmacology, 132, 107, 10.1007/s002130050327 Daugé, 1995, Opioid and CCK systems in anxiety and reward, 152 De Angelis, 1992, The anxiogenic-like effects of pentylenetetrazole in mice treated chronically with carbamazepine or valproate, Methods Find. Exp. Clin. Pharmacol., 14, 767 De Angelis, 2000, The anxiolytic like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test, Pharmacol. Biochem. Behav., 65, 649, 10.1016/S0091-3057(99)00237-3 De Vry, 1993, Shock-induced ultrasonic vocalization in young adults rats: a model for testing putative anti-anxiety drugs, Eur. J. Pharmacol., 249, 331, 10.1016/0014-2999(93)90530-U Fernandez-Guasti, 1990, Evidence for the Involvement of the 5-HT1A receptor in the anxiolytic action of indorate and ipsapirone, Psychopharmacology, 107, 354, 10.1007/BF02244053 File, 1985, Can animal test of anxiety detect anti-panic compounds?, Neurosci. Abstr., 11, 273 File, 1992, Usefulness of animal models with newer anxiolytics, Clin. Neuropharcol., 15, 525A, 10.1097/00002826-199201001-00273 File, 1996, New developments in animal tests of anxiety, 61 Fink, 1994, Behavioural and neurochemical effects of CCK-fragments in animal models of anxiety, Behav. Pharmacol., 5, 30 Gao, 1992, Effect of acute administration of the 5-HT3 receptor antagonist, BRL 46470A, on the behavior of mice in a two compartment light–dark box and during social interactions in their home cage and an unfamiliar neutral cage, Neuropharmacology, 31, 743, 10.1016/0028-3908(92)90035-N Gao, 1993, Effect of acute and subchronic administration of ritanserin on the social behaviour of mice, Neuropharmacology, 32, 265, 10.1016/0028-3908(93)90110-O Górka, 1986, Effects of repeated treatment with antidepressant drugs on the 24 hour behaviour in the light–dark synchronised mice, Pol. J. Pharmacol. Pharm., 38, 493 Griebel, 1995, 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more then 30 years of research, Pharmacol. Ther., 65, 319, 10.1016/0163-7258(95)98597-J Griebel, 1996, Variability in the effects of -5HT related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story?, Pol. J. Pharmacol., 48, 129 Griebel, 1991, m-Chlorophenyl-piperazine enhances neophobic and anxious behaviour in mice, NeuroReport, 2, 627, 10.1097/00001756-199110000-00019 Griebel, 1994, Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents, Psychopharmacology, 113, 463, 10.1007/BF02245224 Griebel, 1996, Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S21357, Pharmacol. Biochem. Behav., 54, 509, 10.1016/0091-3057(95)02215-5 Griebel, 1997, CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours, Behav. Pharmacol., 8, 549, 10.1097/00008877-199711000-00013 Griebel, 1997, A comparative study of the effects of selective and non-selective 5-HT2C receptor subtype antagonists in rat and mouse models of anxiety, Neuropharmacology, 36, 793, 10.1016/S0028-3908(97)00034-8 Griebel, 1998, Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone, Psychopharmacology, 138, 55, 10.1007/s002130050645 Griebel, 2002, J. Pharmacol. Exp. Ther., 301, 333, 10.1124/jpet.301.1.333 Handley, 1995, 5-Hydroxytryptamine pathways in anxiety and its treatment, Pharmacol. Ther., 66, 103, 10.1016/0163-7258(95)00004-Z Handley, 1993, Serotonin mechanisms in animal models of anxiety, Braz. J. Med. Biol. Res., 26, 1 Handley, 1993, Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors, Behav. Brain Res., 58, 203, 10.1016/0166-4328(93)90104-X Hascoët, 1998, A new approach to the light/dark procedure in mice, Pharmacol. Biochem. Behav., 60, 645, 10.1016/S0091-3057(98)00031-8 Hascoët, 1999, Influence of age on behavioural response in the light–dark paradigm, Physiol. Behav., 66, 567, 10.1016/S0031-9384(98)00333-3 Hascoët, 2000, Anxiolytic like effects of antidepressants after acute administration in a four plate test in mice, Pharmacol. Biochem. Behav., 65, 339, 10.1016/S0091-3057(99)00191-4 Hascoët, 2000, The influence of buspirone and its metabolite1-PP on the activity of paroxetine in the mouse light dark paradigm and four plates test, Pharmacol. Biochem. Behav., 67, 45, 10.1016/S0091-3057(00)00293-8 Higgins, 1991, Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists, Psychopharmacology, 104, 545, 10.1007/BF02245664 Hoggs, 1996, A review of the validity and variability of the elevated plus maze as an animal model of anxiety, Pharmacol. Biochem. Behav., 54, 21, 10.1016/0091-3057(95)02126-4 Hughes, 1990, Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity, Proc. Natl. Acad. Sci. U. S. A., 87, 6728, 10.1073/pnas.87.17.6728 Imaizumi, 1993, The behavioural and biochemical effects of thioperamide, a histamine H3-receptor antagonist, in a light/dark test measuring anxiety in mice, Life Sci., 53, 1675, 10.1016/0024-3205(93)90204-G Imaizumi, 1994, Effects of xanthine derivatives in a light/dark test in mice and contribution of adenosine receptors, Methods Find. Exp. Clin. Pharmacol., 16, 639 Imaizumi, 1994, A fully automated apparatus for a light/dark test measuring anxiolytic or anxiogenic effects of drugs in mice, Jpn. J. Psychopharmacol., 14, 83 Kennett, 1994, Evidence that 5-HT2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety, Psychopharmacology, 114, 90, 10.1007/BF02245448 Kilfoil, 1989, Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice, Neuropharmacology, 28, 901, 10.1016/0028-3908(89)90188-3 Kilpatrick, 1990, 5-HT3 receptors, Med. Res. Rev., 10, 441, 10.1002/med.2610100404 Lapin, 1999, A decreased frequency of peeking out from the dark compartment—the only constant index of the effect of anxiogenes on the behaviour of mice in light–darkness chamber, Zh. Vyssh. Nervn. Deiat. IM. I. P. Pavlova May–June, 49, 521 Lightowler, 1994, Anxiolytic like effect of paroxetine in a rat social interaction test, Pharmacol. Biochem. Behav., 49, 281, 10.1016/0091-3057(94)90422-7 Lister, 1990, Ethologically-based models of anxiety disorders, Pharmacol. Ther., 46, 321, 10.1016/0163-7258(90)90021-S Lopez-Rubalcava, 1992, Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics, Pharmacol. Biochem. Behav., 43, 433, 10.1016/0091-3057(92)90173-D Matto, 1995, The mechanism of anxiogenic-like effect of antidepressants on exploratory behaviour in rats, Pharmacol. Toxicol., 76, 53 Metzenauer, 1992, Anxiolytic like action of anpirtoline in a mouse light/dark aversion paradigm, NeuroReport, 3, 527, 10.1097/00001756-199206000-00019 Misslin, 1990, Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice, NeuroReport, 1, 267, 10.1097/00001756-199011000-00025 Nic Dhonnchadha, 2003, Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety, Behav. Brain Res., 10.1016/S0166-4328(02)00311-X Njung'e, 1991, Evaluation of marble-burying behavior as a model of anxiety, Pharmacol. Biochem. Behav., 38, 63, 10.1016/0091-3057(91)90590-X Olivier, 2000, 5-HT3 receptor antagonists and anxiety; a preclinical and clinical review, Eur. Neuropsychopharmacol., 10, 77, 10.1016/S0924-977X(99)00065-6 Onaivi, 1989, Neuropharmacological and physiological validation of a computer-controlled two compartment black and white box for the assessment of anxiety, Prog. Neuro-psychopharmacol. Biol. Psychiatry, 13, 963, 10.1016/0278-5846(89)90047-X Pellow, 1985, Validation of open/closed arm entries in an elevated plus-maze as a measure of anxiety in the rat, J. Neurosci. Methods, 14, 145, 10.1016/0165-0270(85)90031-7 Pletnikov, 1996, Relationship between memory and fear: developmental and pharmacological studies, Pharmacol. Biochem. Behav., 54, 93, 10.1016/0091-3057(95)02167-1 Rodgers, 1997, Animal models of ‘anxiety’: where next?, Behav. Pharmacol., 8, 477, 10.1097/00008877-199711000-00003 Rodgers, 1993, Influence of prior maze experience on behaviour response to diazepam in the elevated plus maze and light/dark test of anxiety in mice, Psychopharmacology, 113, 237, 10.1007/BF02245704 Sanchez, 1995, Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white test box, Pharmacol. Toxicol., 77, 71, 10.1111/j.1600-0773.1995.tb01916.x Sanchez, 1996, 5HT1A receptors play an important role in modulation of behaviour of rats in a two-compartment black and white box, Behav. Pharmacol., 7, 788 Sanchez, 1997, Behavioural profiles of SSRIs in animals models of depression, anxiety and aggression: are they all alike?, Psychopharmacology, 129, 197, 10.1007/s002130050181 Sanchez, 1997, The selective sigma 2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents, J. Pharmacol. Exp. Ther., 283, 1323 Schipper, 1991, Flesinoxan: anxiolytic activity in animal models, 138 Shimada, 1995, The modified light/dark transition test in mice: evaluation of classic and putative anxiolytic and anxiogenic drugs, Gen. Pharmacol., 26, 205, 10.1016/0306-3623(94)00148-G Singh, 1991, The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist, Br. J. Pharmacol., 104, 239, 10.1111/j.1476-5381.1991.tb12413.x Smith, 1986, Anxiolytic action of CGS 9896 on mouse explorator behaviour, Eur. J. Pharmacol., 132, 259, 10.1016/0014-2999(86)90613-8 Stefanski, 1993, Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT3 receptor antagonists, Neuropharmacology, 32, 987, 10.1016/0028-3908(93)90063-9 Treit, 1990, A comparison of anxiolytic and nonanxiolytic agents in the shock probe/burying test for anxiolytics, Pharmacol. Biochem. Behav., 36, 203, 10.1016/0091-3057(90)90151-7 Tyers, 1987, The anxiolytic activities of 5-HT3 antagonists in laboratory animals, Neurosci. Lett., 29, S68 Van Megen, 1996, Cholecystokinin in anxiety, Eur. Neuropsychopharmacol., 6, 263, 10.1016/S0924-977X(96)00038-7 Wieland, 1991, Anxiolytic activity of the progesterone metabolite 5α-pregnan-3α-ol-20-one, Brain Res., 565, 263, 10.1016/0006-8993(91)91658-N Yasumatsu, 1994, The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist, Br. J. Pharmacol., 11, 1170, 10.1111/j.1476-5381.1994.tb14868.x Young, 1988, Comparative effects of zacopride, GR 38032F, buspirone and diazepam in the mouse light/dark exploratory model, Soc. Neurosci. Abstr., 14, 207 Young, 1991, A fully automated light/dark apparatus useful for comparing anxiolytic agents, Pharmacol. Biochem. Behav., 40, 739, 10.1016/0091-3057(91)90078-G Young, 1991, Comparison of routes of administration and time course effects of zacopride and buspirone in mice using an automated light/dark test, Pharmacol. Biochem. Behav., 40, 733, 10.1016/0091-3057(91)90077-F Zernig, 1993, Different behavioral profiles of the non-peptide substance P (NK1) antagonists CP-96,345 and RP 67580 in Swiss albino mice in the black-and-white box, Neurosci. Lett., 151, 64, 10.1016/0304-3940(93)90046-N